2QBR

Crystal structure of ptp1b-inhibitor complex


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free: 0.231 
  • R-Value Work: 0.200 
  • R-Value Observed: 0.200 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.

Wilson, D.P.Wan, Z.K.Xu, W.X.Kirincich, S.J.Follows, B.C.Joseph-McCarthy, D.Foreman, K.Moretto, A.Wu, J.Zhu, M.Binnun, E.Zhang, Y.L.Tam, M.Erbe, D.V.Tobin, J.Xu, X.Leung, L.Shilling, A.Tam, S.Y.Mansour, T.S.Lee, J.

(2007) J Med Chem 50: 4681-4698

  • DOI: 10.1021/jm0702478
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of the insulin and leptin receptor pathways and thus an attractive therapeutic target for diabetes and obesity. Starting with a high micromolar lead compound, structure-based optimizatio ...

    Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of the insulin and leptin receptor pathways and thus an attractive therapeutic target for diabetes and obesity. Starting with a high micromolar lead compound, structure-based optimization of novel PTP1B inhibitors by extension of the molecule from the enzyme active site into the second phosphotyrosine binding site is described. Medicinal chemistry, guided by X-ray complex structure and molecular modeling, has yielded low nanomolar PTP1B inhibitors in an efficient manner. Compounds from this chemical series were found to be actively transported into hepatocytes. This active uptake into target tissues could be one of the possible avenues to overcome the poor membrane permeability of PTP1B inhibitors.


    Related Citations: 
    • Bicyclic and Tricyclic Thiophenes as Protein Tyrosine Phosphatase 1B Inhibitor
      Moretto, A.F., Kirincich, S.J., Xu, W.X., Smith, M.J., Wan, Z.-K., Wilson, D.P., Follows, B.C., Binnun, E., Joseph-Mccarthy, D., Foreman, K., Erbe, D.V., Zhang, Y.-L., Tam, S.K., Tam, S.Y., Lee, J.
      (2006) Bioorg Med Chem 14: 2162

    Organizational Affiliation

    Chemical and Screening Sciences, and Cardiovascular and Metabolic Diseases, Wyeth Research, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, USA.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tyrosine-protein phosphatase non-receptor type 1
A
299Homo sapiensMutation(s): 0 
Gene Names: PTPN1PTP1B
EC: 3.1.3.48
Find proteins for P18031 (Homo sapiens)
Go to UniProtKB:  P18031
NIH Common Fund Data Resources
PHAROS  P18031
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
910
Query on 910

Download CCD File 
A
5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
C20 H16 Br N O5 S
XEQPGVUGYAUMSA-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
910Ki:  470   nM  BindingDB
910Ki:  470   nM  Binding MOAD
910Ki :  470   nM  PDBBind
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free: 0.231 
  • R-Value Work: 0.200 
  • R-Value Observed: 0.200 
  • Space Group: P 31 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 88.946α = 90
b = 88.946β = 90
c = 104.826γ = 120
Software Package:
Software NamePurpose
CNSrefinement
ADSCdata collection
HKL-2000data scaling
CNSphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2007-06-18 
  • Released Date: 2008-03-18 
  • Deposition Author(s): Xu, W.

Revision History 

  • Version 1.0: 2008-03-18
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance